Methionine Synthase Reductase-A66G and -C524T Single Nucleotide Polymorphisms and Prostate Cancer: A Case-Control Trial

Purpose: Some variations in the sequence of methionine synthase reductase (MTRR) gene can increase the risk of
various cancers such as prostate cancer. The aim of this study was to investigate the association between prostate cancer
and the MTRR A66G and C524T gene single nucleotide polymorphisms (SNPs) using an in silico analysis. Methods:
In this case-control study, 218 Iranian men, including 108 men with prostate cancer and 110 prostate cancer-free men,
were enrolled. The MTRR A66G and C524T genotyping was performed by PCR-RFLP. Some of the bioinformatics
tools were employed for the evaluation of polymorphism on the molecular aspects of the MTRR. Results: With regard
to the MTRR A66G polymorphism, the genotype AG (OR: 0.85, 95% CI: 0.47-1.54, p= 0.6014), genotype GG (OR:
0.89, 95% CI: 0.42-1.87, p= 0.7512), and allele G (OR: 0.92, 95% CI: 0.63-1.35, p= 0.6686) were not associated with
prostate cancer risk. However, the data for C524T SNP showed that the genotype CT was associated with prostate
cancer risk (OR: 1.92, 95% CI: 1.06-3.47, p= 0.0308). Further, carriers of the allele T (OR: 1.80, 95% CI: 1.04-3.13,
p= 0.0358) were associated with high risk of prostate cancer. In addition, bioinformatics analysis revealed that C524T
SNP could affect some molecular aspects of the protein structure, while having no effect on the mRNA structure.
Conclusion: The MTRR C524T is a genetic risk factor for prostate cancer; however, the MTRR A66G is not suggested
as a suitable biomarker for prostate cancer. To obtain more reliable results, further studies are recommended to use
larger sample sizes and investigate the effects of environmental factors.